NICE Provides Final Draft Guidance for Lucentis

UK drugs watchdog, NICE, have endorsed the use of Lucentis on the NHS to treat visual impairment caused by diabetic macular oedema after Novartis submitted a revised patient access scheme (PAS) and new drug data. The National Institute for Health and Clinical Excellence published the final draft guidance after a rapid review of the original

Continue Reading

Novartis to Drop NHS Legal Case

Novartis have announced that they are going to drop their legal case against an NHS body that was refusing to fund their eye drug Lucentis. The case was expected to begin next week, but the Swiss firm confirmed that they “will [now] withdraw its request to the court for a judicial review.” In April this

Continue Reading

NICE Reject Breast Cancer Drug Faslodex

England and Wales’ cost watchdog, NICE, yesterday reiterated their assessment that AstraZeneca’s breast cancer drug Faslodex does not represent good use of NHS funds and has not been proven to be better than current treatments. The National Institute for Health and Clinical Excellence (NICE) has published their  final appraisal determination, saying that they do not

Continue Reading

ABPI Conference Pushes Innovation and Collaboration

The UK could be a centre for pharmaceutical innovation but the industry first must collaborate, pharmaceuticals have been told. The dominant theme at the recent ABPI (Association of the British Pharmaceutical Industry) conference was regarding driving innovation and collaboration, both of which are viewed as critical to the future success of the industry, the efficiency

Continue Reading